Aims and scope
Hereditary Cancer in Clinical Practice is an open access journal that publishes articles of interest for the cancer genetics community and serves as a discussion forum for the development appropriate healthcare strategies.
Cancergenetics encompasses a wide variety of disciplines and knowledge in the field is rapidly growing, especially as the amount of information linking genetic differences to inherited cancer predispositions continues expanding. With the increased knowledge of genetic variability and how this relates to cancer risk there is a growing demand not only to disseminate this information into clinical practice but also to enable competent debate concerning how such information is managed and what it implies for patient care.
Topics covered by the journal include but are not limited to:
- Original research articles on any aspect of inherited predispositions to cancer.
- Reviews of inherited cancer predispositions.
- Application of molecular and cytogenetic analysis to clinical decision making.
- Clinical aspects of the management of hereditary cancers.
- Genetic counselling issues associated with cancer genetics.
- The role of registries in improving health care of patients with an inherited predisposition to cancer.
All articles published by Hereditary Cancer in Clinical Practice are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Hereditary Cancer in Clinical Practice you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Hereditary Cancer in Clinical Practice therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Hereditary Cancer in Clinical Practice are included in:
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Hereditary Cancer in Clinical Practice operates an open peer-review system, where the reviewers' names are included on the peer review reports for authors. In addition, if the article is published, the named reviewer reports are published online alongside the article under a Creative Commons Attribution License 4.0. Previous versions of the manuscript and all author responses to the reviewers are available by contacting firstname.lastname@example.org.
The benefit of open peer review is that it increases transparency. The peer reviewers and Editors are fully accountable for the decisions made, bias is reduced as reviewer reports are named, published reports can serve an educational purpose in helping facilitate training and research into peer review, and reviewers can get credit for their work.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to Hereditary Cancer in Clinical Practice should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Hereditary Cancer in Clinical Practice
Articles in Hereditary Cancer in Clinical Practice should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Hered Cancer Clin Pract [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Hered Cancer Clin Pract 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Hereditary Cancer in Clinical Practice offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Hereditary Cancer in Clinical Practice gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Hereditary Cancer in Clinical Practice are included in article alerts and regular email updates. Some may be highlighted on Hereditary Cancer in Clinical Practice’s pages and on the BioMed Central homepage.
In addition, articles published in Hereditary Cancer in Clinical Practice may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Hereditary Cancer in Clinical Practice. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Hereditary Cancer in Clinical Practice you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
2017 Journal Metrics
81 days from submission to first decision
9 days from acceptance to publication
1069.0 Usage Factor
Social Media Impact